No Data
No Data
Even With A 25% Surge, Cautious Investors Are Not Rewarding Zhejiang Jiuzhou Pharmaceutical Co., Ltd's (SHSE:603456) Performance Completely
Zhejiang Jiuzhou Pharmaceutical Co., Ltd's (SHSE:603456) Market Cap Surged CN¥441m Last Week, Individual Investors Who Have a Lot Riding on the Company Were Rewarded
Zhejiang Jiuzhou Pharmaceutical Completes Establishment of German Unit
Zhejiang Jiuzhou Pharmaceutical (603456.SH): Intends to sell 25% equity of Fandah (Suzhou)
On September 9th, Jiuzhou Pharmaceutical (603456.SH) announced that in order to further integrate resources and optimize asset structure, the company has signed a Equity Transfer Agreement with Fangda (Shanghai) and Fangda (Suzhou). Fangda (Shanghai) will acquire 25% equity of Fangda (Suzhou) held by the company for a transaction price of 19.6 million RMB. After this transfer, the company will no longer hold equity of Fangda (Suzhou). Fangda (Suzhou) is an associated company of the company, and the sale of 25% equity of Fangda (Suzhou) will not result in a change in the scope of the company's consolidated financial statements. At the same time, the company expects a disposal loss of 3.6 million RMB from this equity disposal.
Zhejiang Jiuzhou Pharmaceutical (603456.SH) plans to sell 25% equity of Suzhou Fangda Pharmaceutical to raise 19.6 million yuan.
zhejiang jiuzhou pharmaceutical (603456.SH) announced that the company has signed a cooperation agreement with Shanghai Fanda Pharmaceutical Technology Co., Ltd. ("Fanda (Shanghai)...
Despite Delivering Investors Losses of 68% Over the Past 3 Years, Zhejiang Jiuzhou Pharmaceutical (SHSE:603456) Has Been Growing Its Earnings
No Data
No Data